Browse the evidence

ALA was not associated with T2D risk.

Practitioners should note that ALA does not appear to reduce T2D risk, unlike other n-3 fatty acids.

Mean PSA doubling time (PSADT) was similar between LCD (22 months) and control (15 months, P = 0.313) arms.

A low-carbohydrate diet does not adversely affect PSA doubling time in men with recurrent prostate cancer.

Immobilization does not alter mitochondrial H2O2 emission or markers of cellular redox state.

This suggests that oxidative stress may not be a significant factor in muscle atrophy during immobilization.

Passive, low-intensity stretch does not appear to confer beneficial changes in muscle size and architecture.

Practitioners should avoid relying solely on passive stretching for muscle growth.

Rifaximin treatment for 6 weeks did not result in significant changes in alanine aminotransferase (ALT) levels in patients with NASH (55 [33-191] vs. 63 [41-218] IU/L, P = 0.41).

Rifaximin may not be effective for reducing liver inflammation in NASH patients based on ALT levels.

After 12 weeks from baseline, serum ALT levels increased significantly to 83 (30-217) IU/L (P = 0.02).

Monitoring ALT levels is important as they may worsen after rifaximin treatment in NASH patients.

There was no significant change in telomere length at 6 months.

Weight loss interventions may not affect telomere length in the short term.

There is a need for more research on the anabolic potential of non-animal-derived protein sources.

More research is needed to evaluate the effectiveness of non-animal protein sources for muscle health.

INV-202 was well tolerated with no serious or severe treatment-emergent adverse events.

INV-202 appears to be a safe option for individuals with metabolic syndrome.

Greater male variation in basal energy expenditure may be explained by greater male variation in the size of energy-demanding organs.

Understanding organ size variation may help tailor nutritional strategies for energy expenditure.

Metformin failed to prove beneficial effects in MASLD progression.

Avoid using metformin for treating MASLD progression as it has not shown benefits.

Adipocyte and preadipocyte formation in scABD and scFEM depots correlates positively with VAT/TAT.

Understanding the relationship between adipocyte formation and VAT/TAT can inform strategies for managing obesity.

Glucose is essential for the functioning of the pentose phosphate pathway (PPP) and cannot be substituted by other metabolites.

Practitioners should recognize the critical role of glucose in metabolic pathways.

Semaglutide improves the function and inflammatory status of endothelial progenitor cells (EPCs) by inhibiting LPS-induced macrophage expression of miR-155 in exosomes.

Semaglutide may be beneficial in improving endothelial function in obesity-related inflammation.

LPS-induced macrophage exosomes reduce the cellular activity, migratory capacity, and tube-forming ability of EPCs.

Inflammation from macrophage exosomes can impair endothelial repair mechanisms.

Semaglutide alleviated metabolic disorders, ameliorated myocardial fibrosis, improved cardiac function, antagonized oxidative stress, and suppressed cardiomyocyte apoptosis in diabetic mice.

Semaglutide may be beneficial for improving heart health in diabetic patients.

Whey and pea protein compared to water supplementation had no significant effects on post-exercise delayed onset of muscle soreness (DOMS) and fitness tests.

Protein supplementation may not significantly reduce muscle soreness or improve fitness performance after exercise.

Gastrointestinal adverse events occur commonly with semaglutide, and other serious adverse events have been reported.

Healthcare providers should monitor patients for gastrointestinal and other serious adverse events while on semaglutide.

There are existing knowledge gaps in the molecular and cellular processes underlying exercise-induced benefits and adaptations.

Researchers should focus on addressing these gaps to advance the understanding of exercise physiology.

Fructose resets ATP levels to a lower level in the cell, suppressing mitochondrial function.

Understanding fructose's impact on ATP may inform dietary recommendations.

The development of new drug combinations may provide alternative treatment options for OSA.

Practitioners should explore new drug combinations as potential treatments for OSA.

Tirzepatide treatment significantly decreased Alt-Ext-induced IL-5 and IL-13 levels in lung homogenates compared with vehicle treatment.

Tirzepatide may help reduce allergic inflammation in obese asthma patients.

There was no benefit from ILI for individuals in the third tertile of frailty index, with a hazard ratio of 1.15.

Practitioners should be cautious in recommending intensive lifestyle interventions for more frail individuals.

The incidence of gastrointestinal adverse effects with tirzepatide was similar to that of semaglutide.

Tirzepatide may have a similar safety profile regarding gastrointestinal effects compared to semaglutide.